Abstract: A process for dissolving modified cellulose includes contacting modified cellulose solution with at least one non-solvent to form a plurality of modified cellulose particles.

Abstract: A process for dissolving modified cellulose is disclosed. The process includes contacting modified cellulose with a solvent in a mixture to form swelled modified cellulose and then contacting the mixture with a salt to dissolve the swelled modified cellulose.

Abstract: A process for dissolving modified cellulose includes contacting modified cellulose solution with at least one multivalent cation to form a plurality of modified cellulose particles.

Abstract: A process for dissolving modified cellulose includes contacting modified cellulose solution with at least one non-solvent to form a plurality of modified cellulose particles.

Abstract: A process for dissolving modified cellulose includes contacting modified cellulose solution with at least one neutralizing agent to form a plurality of modified cellulose particles.

Abstract: A process for forming microspheres is disclosed. The process includes contacting a solvent with a modified cellulose to form a solution; contacting the modified cellulose solution with at least one bioactive agent to form a discontinuous phase liquid; contacting the discontinuous phase liquid with a continuous phase liquid to form an emulsion; and contacting the emulsion with a third phase liquid to extract the solvent from the emulsion, thereby forming a plurality of modified cellulose microspheres.

Abstract: The present invention relates to the use of novel pyrrolo[2,3-b]]pyrazines wherein all variable substituents are defined as described herein, which are SYK inhibitors and are useful for the treatment of auto-immune and inflammatory diseases.

Abstract: A process for forming microspheres is disclosed. The process includes contacting a solvent with a modified cellulose to form a solution; contacting the modified cellulose solution with at least one bioactive agent to form a discontinuous phase liquid; contacting the discontinuous phase liquid with a continuous phase liquid to form an emulsion; and contacting the emulsion with a third phase liquid to extract the solvent from the emulsion, thereby forming a plurality of modified cellulose microspheres.

Abstract: This application discloses compounds according to generic Formula I wherein all variables are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formula I and at least one carrier, diluent or excipient.

Abstract: The present invention relates to the use of novel compounds of formula I: wherein all variable substituents are defined as described herein, which are SYK inhibitors and are useful for the treatment of auto-immune and inflammatory diseases.

Abstract: The present invention relates to the use of novel compounds of formula (I), wherein all variable substituents are defined as described herein, which are SYK inhibitors and are useful for the treatment of auto-immune and inflammatory diseases.

Abstract: The present invention relates to the use of novel pyrrolo[2,3-b]]pyrazines wherein all variable substituents are defined as described herein, which are SYK inhibitors and are useful for the treatment of auto-immune and inflammatory diseases.

Abstract: The present invention relates to the use of novel triazolopyridine derivatives of formula I: wherein all variable substituents are defined as described herein, which are SYK inhibitors and are useful for the treatment of auto-immune and inflammatory diseases.

Abstract: Crosslinked polymers, methods for their preparation and use, are described in which the crosslinked polymers are formed from at least two polymer precursors, one of which is designed, upon degradation of the crosslinked polymer, to release the second polymer precursor in its original, unmodified chemical form.

Abstract: A process for dissolving modified cellulose is disclosed. The process includes contacting modified cellulose with a solvent in a mixture to form swelled modified cellulose and then contacting the mixture with a salt to dissolve the swelled modified cellulose.

Abstract: Systems and methods for choice experiments to model user behavior are disclosed. Choice experiment surveys require respondents to choose by performing trade-offs between combinations of features included in alternatives under consideration. Users specify constraints and an attribute space of features to investigate, and generate candidate experimental designs based on the constraints and attributes. Users select an optimum design tailored to the problem to be solved, instead of having to modify their problem to match a known experimental design. An online survey assembly module generates survey templates used by a data collection and sampling unit to display treatments to survey respondents. A model generation module analysis the collected data, and a model explorer module enables exploration of results. The system has the advantage of making choice modelling accessible to a wider range of users, and enables considerable freedom and scope to investigate problems of specific interest.

Abstract: The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula I, wherein the variables are defined as described herein, which inhibit JAK and SYK and are useful for the treatment of auto-immune and inflammatory diseases.

Abstract: A process for dissolving modified cellulose includes contacting modified cellulose solution with at least one neutralizing agent to form a plurality of modified cellulose particles.

Abstract: A process for dissolving modified cellulose includes contacting modified cellulose solution with at least one multivalent cation to form a plurality of modified cellulose particles.

Abstract: A process for dissolving modified cellulose includes contacting modified cellulose solution with at least one non-solvent to form a plurality of modified cellulose particles.